Logo image of RIGL

RIGEL PHARMACEUTICALS INC (RIGL) Stock Fundamental Analysis

NASDAQ:RIGL - Nasdaq - US7665597024 - Common Stock - Currency: USD

18.95  -0.78 (-3.95%)

After market: 18.81 -0.14 (-0.74%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to RIGL. RIGL was compared to 562 industry peers in the Biotechnology industry. Both the profitability and the financial health of RIGL get a neutral evaluation. Nothing too spectacular is happening here. An interesting combination arises when we look at growth and value: RIGL is growing strongly while it also seems undervalued. This makes RIGL very considerable for value and growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

RIGL had positive earnings in the past year.
In the past year RIGL had a positive cash flow from operations.
RIGL had negative earnings in 4 of the past 5 years.
In multiple years RIGL reported negative operating cash flow during the last 5 years.
RIGL Yearly Net Income VS EBIT VS OCF VS FCFRIGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

RIGL's Return On Assets of 21.13% is amongst the best of the industry. RIGL outperforms 97.69% of its industry peers.
RIGL's Return On Equity of 200.24% is amongst the best of the industry. RIGL outperforms 99.64% of its industry peers.
RIGL has a better Return On Invested Capital (31.74%) than 98.93% of its industry peers.
Industry RankSector Rank
ROA 21.13%
ROE 200.24%
ROIC 31.74%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RIGL Yearly ROA, ROE, ROICRIGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

RIGL has a Profit Margin of 18.31%. This is amongst the best in the industry. RIGL outperforms 95.37% of its industry peers.
Looking at the Operating Margin, with a value of 21.63%, RIGL belongs to the top of the industry, outperforming 95.55% of the companies in the same industry.
RIGL's Gross Margin of 89.64% is amongst the best of the industry. RIGL outperforms 91.99% of its industry peers.
RIGL's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 21.63%
PM (TTM) 18.31%
GM 89.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
RIGL Yearly Profit, Operating, Gross MarginsRIGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

6

2. Health

2.1 Basic Checks

RIGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
RIGL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RIGL has less shares outstanding
Compared to 1 year ago, RIGL has an improved debt to assets ratio.
RIGL Yearly Shares OutstandingRIGL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RIGL Yearly Total Debt VS Total AssetsRIGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

RIGL has an Altman-Z score of -7.15. This is a bad value and indicates that RIGL is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of RIGL (-7.15) is worse than 67.08% of its industry peers.
RIGL has a debt to FCF ratio of 1.69. This is a very positive value and a sign of high solvency as it would only need 1.69 years to pay back of all of its debts.
RIGL's Debt to FCF ratio of 1.69 is amongst the best of the industry. RIGL outperforms 95.02% of its industry peers.
RIGL has a Debt/Equity ratio of 2.42. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 2.42, RIGL is doing worse than 82.38% of the companies in the same industry.
Although RIGL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 2.42
Debt/FCF 1.69
Altman-Z -7.15
ROIC/WACC3
WACC10.57%
RIGL Yearly LT Debt VS Equity VS FCFRIGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

RIGL has a Current Ratio of 2.20. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
RIGL's Current ratio of 2.20 is on the low side compared to the rest of the industry. RIGL is outperformed by 74.20% of its industry peers.
RIGL has a Quick Ratio of 2.13. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
RIGL's Quick ratio of 2.13 is on the low side compared to the rest of the industry. RIGL is outperformed by 72.78% of its industry peers.
Industry RankSector Rank
Current Ratio 2.2
Quick Ratio 2.13
RIGL Yearly Current Assets VS Current LiabilitesRIGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 272.50% over the past year.
Looking at the last year, RIGL shows a very strong growth in Revenue. The Revenue has grown by 68.74%.
Measured over the past years, RIGL shows a very strong growth in Revenue. The Revenue has been growing by 24.77% on average per year.
EPS 1Y (TTM)272.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%226%
Revenue 1Y (TTM)68.74%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%80.58%

3.2 Future

Based on estimates for the next years, RIGL will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.07% on average per year.
Based on estimates for the next years, RIGL will show a quite strong growth in Revenue. The Revenue will grow by 11.81% on average per year.
EPS Next Y21.89%
EPS Next 2Y30.83%
EPS Next 3Y16.04%
EPS Next 5Y14.07%
Revenue Next Year18.33%
Revenue Next 2Y16.01%
Revenue Next 3Y14.11%
Revenue Next 5Y11.81%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RIGL Yearly Revenue VS EstimatesRIGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
RIGL Yearly EPS VS EstimatesRIGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 9.15, which indicates a very decent valuation of RIGL.
Based on the Price/Earnings ratio, RIGL is valued cheaply inside the industry as 97.51% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of RIGL to the average of the S&P500 Index (25.82), we can say RIGL is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 11.78, the valuation of RIGL can be described as reasonable.
Based on the Price/Forward Earnings ratio, RIGL is valued cheaper than 95.73% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.76, RIGL is valued a bit cheaper.
Industry RankSector Rank
PE 9.15
Fwd PE 11.78
RIGL Price Earnings VS Forward Price EarningsRIGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, RIGL is valued cheaper than 98.40% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, RIGL is valued cheaply inside the industry as 97.69% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 9.58
EV/EBITDA 6.25
RIGL Per share dataRIGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of RIGL may justify a higher PE ratio.
RIGL's earnings are expected to grow with 16.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.42
PEG (5Y)N/A
EPS Next 2Y30.83%
EPS Next 3Y16.04%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RIGL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RIGEL PHARMACEUTICALS INC

NASDAQ:RIGL (5/23/2025, 8:53:05 PM)

After market: 18.81 -0.14 (-0.74%)

18.95

-0.78 (-3.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners69.99%
Inst Owner Change-47.99%
Ins Owners2.63%
Ins Owner Change7.55%
Market Cap338.64M
Analysts76.67
Price Target34.34 (81.21%)
Short Float %10.64%
Short Ratio7.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1609.36%
Min EPS beat(2)67.95%
Max EPS beat(2)3150.77%
EPS beat(4)4
Avg EPS beat(4)1093.78%
Min EPS beat(4)67.95%
Max EPS beat(4)3150.77%
EPS beat(8)7
Avg EPS beat(8)564.17%
EPS beat(12)11
Avg EPS beat(12)391.46%
EPS beat(16)13
Avg EPS beat(16)293.55%
Revenue beat(2)2
Avg Revenue beat(2)14.16%
Min Revenue beat(2)9.15%
Max Revenue beat(2)19.17%
Revenue beat(4)4
Avg Revenue beat(4)16.43%
Min Revenue beat(4)8.08%
Max Revenue beat(4)29.32%
Revenue beat(8)7
Avg Revenue beat(8)8.14%
Revenue beat(12)10
Avg Revenue beat(12)14.32%
Revenue beat(16)11
Avg Revenue beat(16)10.8%
PT rev (1m)0%
PT rev (3m)10.38%
EPS NQ rev (1m)-3.39%
EPS NQ rev (3m)-28.3%
EPS NY rev (1m)8.09%
EPS NY rev (3m)0.4%
Revenue NQ rev (1m)-0.38%
Revenue NQ rev (3m)0.1%
Revenue NY rev (1m)3.75%
Revenue NY rev (3m)3.19%
Valuation
Industry RankSector Rank
PE 9.15
Fwd PE 11.78
P/S 1.67
P/FCF 9.58
P/OCF 9.51
P/B 18.24
P/tB N/A
EV/EBITDA 6.25
EPS(TTM)2.07
EY10.92%
EPS(NY)1.61
Fwd EY8.49%
FCF(TTM)1.98
FCFY10.43%
OCF(TTM)1.99
OCFY10.51%
SpS11.36
BVpS1.04
TBVpS-0.44
PEG (NY)0.42
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 21.13%
ROE 200.24%
ROCE 40.18%
ROIC 31.74%
ROICexc 107.63%
ROICexgc 605.47%
OM 21.63%
PM (TTM) 18.31%
GM 89.64%
FCFM 17.4%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score6
Asset Turnover1.15
Health
Industry RankSector Rank
Debt/Equity 2.42
Debt/FCF 1.69
Debt/EBITDA 0.97
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 6.27
Cash Conversion 76.77%
Profit Quality 95.04%
Current Ratio 2.2
Quick Ratio 2.13
Altman-Z -7.15
F-Score6
WACC10.57%
ROIC/WACC3
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)272.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%226%
EPS Next Y21.89%
EPS Next 2Y30.83%
EPS Next 3Y16.04%
EPS Next 5Y14.07%
Revenue 1Y (TTM)68.74%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%80.58%
Revenue Next Year18.33%
Revenue Next 2Y16.01%
Revenue Next 3Y14.11%
Revenue Next 5Y11.81%
EBIT growth 1Y398.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.99%
EBIT Next 3Y76.86%
EBIT Next 5YN/A
FCF growth 1Y152.41%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y168.2%
OCF growth 3Y74.92%
OCF growth 5YN/A